Recombinant Mouse PCSK9 Protein (Met1-Gln694), MlgG1 Fc-tagged

• Cat.No.: PCSK9-812M
• Product Overview: Recombinant Mouse PCSK9 Protein (NP_705793.1) (Met1-Gln694) was produced by HEK293 Cells expression system. This protein was expressed with the Fc region of mouse IgG1 at the C-terminus.

Specification

• Description: Proprotein convertase subtilisin/kexin type 9 (PCSK9), also known as NARC1 (neural apoptosis regulated convertase), which is a newly identified human secretory subtilase belonging to the proteinase K subfamily of the secretory subtilase family. PCSK9 protein is an enzyme which in humans is encoded by the PCSK9 gene with orthologs found across many species. It is expressed in neuroepithelioma, colon carcinoma, hepatic and pancreatic cell lines, and in Schwann cells. PCSK9 protein is highly expressed in the liver and regulates low density lipoprotein receptor (LDLR) protein levels. Inhibition of PCSK9 protein function is currently being explored as a means of lowering cholesterol levels. Thereby, PCSK9 protein is regarded as a new strategy to treat hypercholesterolemia. PCSK9 protein contributes to cholesterol homeostasis and may have a role in the differentiation of cortical neurons.
• Source: HEK293
• Species: Mouse
• Tag: mFc
• Predicted N Terminal: Gln 35
• Form: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Molecular Mass: The recombinant mouse PCSK9 consists of 894 amino acids and predicts a molecular mass of 97.6 kDa.
• Protein length: Met1-Gln694
• Endotoxin: < 1.0 EU per μg protein as determined by the LAL method.
• Purity: > 95 % as determined by SDS-PAGE.
• Stability: Samples are stable for up to twelve months from date of receipt at -70 centigrade.
• Storage: Store it under sterile conditions at -20 centigrade to -80 centigrade. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 mg/ml. Centrifuge the vial at 4℃ before opening to recover the entire contents.
• Shipping: In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.
  Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.

Gene Information

• Gene Name: Pcsk9 proprotein convertase subtilisin/kexin type 9 [ Mus musculus ]
• Official Symbol: PCSK9
• Synonyms: PCSK9; NARC-1; FH3; PC9; Narc1; HCHOLA3; AI415265; AI747682; MGC47409
• Gene ID: 100102
• mRNA Refseq: NM_153565
• Protein Refseq: NP_705793
• UniProt ID: Q80W65

Reviews

11/13/2022

In immunological experiments, it was found that it had good antigenicity and could induce target immune responses.

07/07/2022

It promoted cell growth and proliferation.

03/04/2022

High catalytic efficiency.

Q&As

Is there a relationship between genetic mutations in the PCSK9 protein and cardiovascular disease?

Yes, some studies suggest that mutations in the PCSK9 protein gene may increase the risk of cardiovascular disease. For example, some PCSK9 mutations can cause their dysfunction, resulting in hypercholesterolemia and cardiovascular disease.

How can PCSK9 protein be used for vaccine development?

PCSK9 protein is combined with immune adjuvants to make a vaccine, or mutated PCSK9 protein to induce an immune response to it, inhibit PCSK9 expression in vivo, increase LDLR levels and reduce serum cholesterol levels.

What is the relationship between PCSK9 protein and obesity?

This protein may have a regulatory effect on weight and obesity, and it is associated with glucose and endocannabinin homeostasis studies have linked PCSK9 to the development of obesity and diabetes.

What are the new prospects for future therapies that inhibit PCSK9 protein?

Several new anti-PCSK9 drugs are already being studied and developed, including oral drugs and gene chromosome therapies, and some drugs have advanced to early stages of clinical trials, providing new options for the treatment of PCSK9 proteins.

What drugs are currently available to inhibit the PCSK9 protein?

Currently on the market to inhibit PCSK9 protein drugs include alirocumab and evolocumab.

What is the relationship between PCSK9 protein and hypercholesterolemia?

PCSK9 protein can degrade LDLR protein, so its overexpression will lead to a decrease in LDLR's ability to be cleared, leading to hypercholesterolemia.